Potassium Voltage Gated Channel Subfamily A Member 3 (Voltage Gated Potassium Channel Subunit Kv1.3 or KCNA3) - Pipeline Review, H1 2016

  • ID: 3788908
  • Report
  • 61 pages
  • Global Markets Direct
1 of 6

FEATURED COMPANIES

  • Amgen Inc.
  • Axxam SpA
  • Bionomics Limited
  • Johnson & Johnson
  • Kineta, Inc.
  • Sevion Therapeutics, Inc.
  • MORE
Potassium Voltage Gated Channel Subfamily A Member 3 (Voltage Gated Potassium Channel Subunit Kv1.3 or KCNA3) - Pipeline Review, H1 2016

Summary

‘Potassium Voltage Gated Channel Subfamily A Member 3 (Voltage Gated Potassium Channel Subunit Kv1.3 or KCNA3) - Pipeline Review, H1 2016’, provides in depth analysis on Potassium Voltage Gated Channel Subfamily A Member 3 (Voltage Gated Potassium Channel Subunit Kv1.3 or KCNA3) targeted pipeline therapeutics.

The report provides comprehensive information on the Potassium Voltage Gated Channel Subfamily A Member 3 (Voltage Gated Potassium Channel Subunit Kv1.3 or KCNA3), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Potassium Voltage Gated Channel Subfamily A Member 3 (Voltage Gated Potassium Channel Subunit Kv1.3 or KCNA3) targeted therapeutics development and features dormant and discontinued projects.

Our report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape for Potassium Voltage Gated Channel Subfamily A Member 3 (Voltage Gated Potassium Channel Subunit Kv1.3 or KCNA3)
- The report reviews Potassium Voltage Gated Channel Subfamily A Member 3 (Voltage Gated Potassium Channel Subunit Kv1.3 or KCNA3) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Potassium Voltage Gated Channel Subfamily A Member 3 (Voltage Gated Potassium Channel Subunit Kv1.3 or KCNA3) targeted therapeutics and enlists all their major and minor projects
- The report assesses Potassium Voltage Gated Channel Subfamily A Member 3 (Voltage Gated Potassium Channel Subunit Kv1.3 or KCNA3) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Potassium Voltage Gated Channel Subfamily A Member 3 (Voltage Gated Potassium Channel Subunit Kv1.3 or KCNA3) targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Potassium Voltage Gated Channel Subfamily A Member 3 (Voltage Gated Potassium Channel Subunit Kv1.3 or KCNA3)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Potassium Voltage Gated Channel Subfamily A Member 3 (Voltage Gated Potassium Channel Subunit Kv1.3 or KCNA3) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
READ MORE
Note: Product cover images may vary from those shown
2 of 6

FEATURED COMPANIES

  • Amgen Inc.
  • Axxam SpA
  • Bionomics Limited
  • Johnson & Johnson
  • Kineta, Inc.
  • Sevion Therapeutics, Inc.
  • MORE
List of Tables

List of Figures

Introduction

Report Coverage

Potassium Voltage Gated Channel Subfamily A Member 3 (Voltage Gated Potassium Channel Subunit Kv1.3 or KCNA3) Overview

Therapeutics Development

Potassium Voltage Gated Channel Subfamily A Member 3 (Voltage Gated Potassium Channel Subunit Kv1.3 or KCNA3) - Products under Development by Stage of Development

Potassium Voltage Gated Channel Subfamily A Member 3 (Voltage Gated Potassium Channel Subunit Kv1.3 or KCNA3) - Products under Development by Therapy Area

Potassium Voltage Gated Channel Subfamily A Member 3 (Voltage Gated Potassium Channel Subunit Kv1.3 or KCNA3) - Products under Development by Indication

Potassium Voltage Gated Channel Subfamily A Member 3 (Voltage Gated Potassium Channel Subunit Kv1.3 or KCNA3) - Pipeline Products Glance

Early Stage Products

Potassium Voltage Gated Channel Subfamily A Member 3 (Voltage Gated Potassium Channel Subunit Kv1.3 or KCNA3) - Products under Development by Companies

Potassium Voltage Gated Channel Subfamily A Member 3 (Voltage Gated Potassium Channel Subunit Kv1.3 or KCNA3) - Products under Development by Universities/Institutes

Potassium Voltage Gated Channel Subfamily A Member 3 (Voltage Gated Potassium Channel Subunit Kv1.3 or KCNA3) - Therapeutics Assessment

Assessment by Monotherapy/Combination Products

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Potassium Voltage Gated Channel Subfamily A Member 3 (Voltage Gated Potassium Channel Subunit Kv1.3 or KCNA3) - Companies Involved in Therapeutics Development

Amgen Inc.

Axxam SpA

Bionomics Limited

conoGenetix biosciences GmbH

Johnson & Johnson

Kineta, Inc.

Sevion Therapeutics, Inc.

Potassium Voltage Gated Channel Subfamily A Member 3 (Voltage Gated Potassium Channel Subunit Kv1.3 or KCNA3) - Drug Profiles

BNC-164 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

cgtx-A - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

cgtx-F - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

cgtx-G - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

dalazatide - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

KPI-150 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

KPI-190 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

OSK-1 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Recombinant Peptide to Block Kv1.3 Ion Channel for Autoimmune Diseases - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Recombinant Peptides to Block Kv1.3 Channel for Autoimmune Diseases - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Block Kv1.3 Ion Channel for Multiple Sclerosis, Immunology, Inflammatory Bowel Disease and Type 1 Diabetes - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SVN-001 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Synthetic Peptides to Block Potassium Voltage-Gated Channel Subfamily A Member 3 (Kv1.3) for Autoimmune Disorders - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Potassium Voltage Gated Channel Subfamily A Member 3 (Voltage Gated Potassium Channel Subunit Kv1.3 or KCNA3) - Dormant Projects

Potassium Voltage Gated Channel Subfamily A Member 3 (Voltage Gated Potassium Channel Subunit Kv1.3 or KCNA3) - Featured News & Press Releases

Jun 10, 2016: Alliance for Children Therapeutics Presents Dalazatide Data Demonstrating Positive Response in Lupus

May 23, 2016: KPI Therapeutics to Present Updated Dalazatide Study Data in Lupus

May 12, 2016: KPI Therapeutics Presents Dalazatide Plaque Psoriasis Data at Dermatology Conference

Feb 08, 2016: KPI Therapeutics Initiates Research Program In Skin Diseases

Feb 08, 2016: KPI Therapeutics Initiates Research Program In Eye Diseases

Nov 10, 2015: Kineta, Seattle Children’s Research Institute Present New Data Demonstrating Positive, Predictive Responses to Dalazatide In Lupus

Nov 09, 2015: Kineta Presents New Data Demonstrating Positive, Predictive Responses to Dalazatide in Psoriasis Patients and in Lupus, ANCA Vasculitis Studies at American College of Rheumatology Annual Meeting

Aug 08, 2015: Kineta Presents Updated Data on Dalazatide Clinical Trial at 12th World Congress on Inflammation

Jun 17, 2015: ACT Research Suggests Role for Dalazatide in Blocking T Cells from Patients with Lupus

Jun 09, 2015: Kineta To Give Update On Dalazatide Clinical Trial Results At BIO International Meeting

Jun 05, 2015: Sevion Therapeutics to Present at International Antibody Meeting

May 05, 2015: Kineta Announces Promising Top-line Clinical Results for Dalazatide; Target Implicated in Broad Array of Autoimmune Diseases

May 04, 2015: Sevion Therapeutics Presents Cow Antibody Platform at PEGS 2015

Apr 21, 2015: Kineta, University of Groningen Present New, Positive Data for Dalazatide in ANCA Vasculitis, an Orphan Disease

Mar 19, 2015: Kineta’s ShK-186 Shows Encouraging Early Results as Potential Therapy for Autoimmune Eye Diseases

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer 61List of Tables

Number of Products under Development for, H1 2016

Number of Products under Development by Therapy Area, H1 2016

Number of Products under Development by Indication, H1 2016

Comparative Analysis by Early Stage Products, H1 2016

Number of Products under Development by Companies, H1 2016

Products under Development by Companies, H1 2016

Products under Development by Companies, H1 2016 (Contd..1)

Number of Products under Investigation by Universities/Institutes, H1 2016

Products under Investigation by Universities/Institutes, H1 2016

Assessment by Monotherapy/Combination Products, H1 2016

Number of Products by Stage and Mechanism of Action, H1 2016

Number of Products by Stage and Route of Administration, H1 2016

Number of Products by Stage and Molecule Type, H1 2016

Pipeline by Amgen Inc., H1 2016

Pipeline by Axxam SpA, H1 2016

Pipeline by Bionomics Limited, H1 2016

Pipeline by conoGenetix biosciences GmbH, H1 2016

Pipeline by Johnson & Johnson, H1 2016

Pipeline by Kineta, Inc., H1 2016

Pipeline by Sevion Therapeutics, Inc., H1 2016

Dormant Projects, H1 2016

Dormant Projects (Contd..1), H1 2016 49List of Figures

Number of Products under Development for, H1 2016

Number of Products under Development by Therapy Area, H1 2016

Number of Products under Development by Top 10 Indication, H1 2016

Comparative Analysis by Early Stage Products, H1 2016

Assessment by Monotherapy/Combination Products, H1 2016

Number of Products by Stage and Mechanism of Actions, H1 2016

Number of Products by Routes of Administration, H1 2016

Number of Products by Stage and Routes of Administration, H1 2016

Number of Products by Molecule Types, H1 2016

Number of Products by Stage and Molecule Type, H1 2016
Note: Product cover images may vary from those shown
3 of 6

Loading
LOADING...

4 of 6

FEATURED COMPANIES

  • Amgen Inc.
  • Axxam SpA
  • Bionomics Limited
  • Johnson & Johnson
  • Kineta, Inc.
  • Sevion Therapeutics, Inc.
  • MORE
Potassium Voltage Gated Channel Subfamily A Member 3 (Voltage Gated Potassium Channel Subunit Kv1.3 or KCNA3) pipeline Target constitutes close to 13 molecules. Out of which approximately 12 molecules are developed by Companies and remaining by the Universities/Institutes. Our latest report Potassium Voltage Gated Channel Subfamily A Member 3 – Pipeline Review, H1 2016, outlays comprehensive information on the Potassium Voltage Gated Channel Subfamily A Member 3 (Voltage Gated Potassium Channel Subunit Kv1.3 or KCNA3) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.

Potassium Voltage Gated Channel Subfamily A Member 3 (Voltage Gated Potassium Channel Subunit Kv1.3 or KCNA3) Potassium voltage-gated channel, shaker-related subfamily, member 3, also known as KCNA3 or Kv1.3 is a protein encoded by the KCNA3 gene. It mediates the voltage-dependent potassium ion permeability of excitable membranes. Blockade of Kv1.3 channels in effector-memory T cells suppresses calcium signaling, cytokine production (interferon-gamma, interleukin 2), and cell proliferation. Kv1.3 is expressed in the inner mitochondrial membrane in lymphocytes. Kv1.3 modulation is one of many mechanisms that contribute to apoptosis. The molecules developed by Companies in Phase I, Preclinical and Discovery stages are 1, 9 and 2 respectively. Similarly, the Universities portfolio in Discovery stages comprises 1 molecules, respectively.

Furthermore, this report also reviews key players involved in Potassium Voltage Gated Channel Subfamily A Member 3 (Voltage Gated Potassium Channel Subunit Kv1.3 or KCNA3) targeted therapeutics development, features dormant and discontinued projects and latest news and press releases. Driven by data built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.
Note: Product cover images may vary from those shown
5 of 6
Amgen Inc.
Axxam SpA
Bionomics Limited
conoGenetix biosciences GmbH
Johnson & Johnson
Kineta, Inc.
Sevion Therapeutics, Inc.
Note: Product cover images may vary from those shown
6 of 6
Note: Product cover images may vary from those shown
Adroll
adroll